Unlearn.AI has secured an additional $15M for its machine learning technology that generates "digital twins" of human patients for clinical trials.
The company also announced that OpenAI's CTO, Mira Murati, is joining Unlearn.AI's board.
Murati told Reuters that Unlearn's team is developing AI applications that have the potential "to revolutionize healthcare, diagnostics, and treatment."
- The San Francisco startup partners with pharma companies to create computer models of patients based on historical data gathered from many clinical trials and studies.
- These models can replicate actual patients for drug and academic-related trials, lowering the number of participants needed for the placebo/control arm of the research.
- Commerizliving its tech to drugmakers will require approval from the FDA and other regulators, according to CEO Charles Fisher. The startup is focused on Phase 3 clinical trials.
Unlearn has raised $85M to date, including a $50M Series B funding round last spring.
- The latest funding, which values Unlearn at $265M, will help it accelerate regulatory approvals and expand its partnerships.
